HOME >> MEDICINE >> NEWS
Drug to treat ADHD has similar effect on children with reading disorders

The drug methylphenidate (brand name Ritalin) increased activity in brains of children with attention-deficit/hyperactivity disorder (ADHD) as well as those with a reading disorder, researchers at Yale report in the American Journal of Psychiatry.

"During a test of divided attention, Ritalin increased activation in the basal ganglia, a structure of the brain involved in cognition and behavior," said first author Keith Shafritz, former graduate student in the interdepartmental Neuroscience Program at Yale and now a research associate at Duke University Medical Center. "We saw this activation in children with ADHD and those with reading disorder."

The study used functional magnetic resonance imaging (fMRI) to analyze the effect of the drug on brain function. Researchers found that adolescents with ADHD or reading disorder who were on placebo (not medicated) had less activation of the basal ganglia than a group of healthy participants. When the same participants received Ritalin, the drug normalized the activation, which relates to the amount of blood flow to a specific brain region in response to a cognitive task.

ADHD is characterized by inattention, but previous neuroimaging studies have examined the brain dysfunction associated with impulsivity. "This is one of few studies that used a test for attention rather than a cognitive test for impulsivity," said Shafritz. "It is also the first study, using fMRI to find that the attention circuitry in the brain is directly affected by ADHD."

The 27 study participants, ages 14 to 18 with either ADHD or reading disorder, were randomly assigned to receive Ritalin first or placebo first and didn't know to which group they were assigned. While in the MRI, the participants were given auditory or visual performance tasks to decide whether they saw or heard a real English word or a nonsense word. Their results were compared to a group of 14 healthy adolescents who were not given Rital
'"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
13-Dec-2004


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. Hormonal treatment improves survival in high-risk prostate cancer patients
3. Chronic pain treatments more effective when taken together, new study shows
4. Brain activity prior to treatment flags vulnerability to antidepressant side effects
5. Unexpected benefit seen in treating HER-2 breast cancer with new preoperative drug combo
6. OHSU scientists test medication to treat involuntary weight loss
7. Cultural and social factors influence prostate cancer treatment
8. Research offers hope of new treatments for liver damage
9. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
10. Risky surgery not always necessary to treat cervical disease
11. Stanford patient is first to test new treatment for peripheral arterial disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Drug treat ADHD has similar effect children with reading disorders

(Date:10/22/2014)... 2014 On Saturday, October 25, 2014, the ... family health and fitness fair ¡Vive tu vida! Get Up! ... good nutrition for better health and wellness for people of ... and open to the public, will be held at Dean ... am to 1:00 pm. , “¡Vive tu Vida! Get ...
(Date:10/22/2014)... 2014 Isabel Healthcare will ... Professions (ASAHP) Conference on October 22-24 in Las Vegas, ... in a panel discussion on Technology in Health Professions ... provides a diagnostic decision support tool and clinical education ... of students and clinical learners. The Isabel tools help ...
(Date:10/22/2014)... (HealthDay News) -- The United States is now ... nations of West Africa land at one of ... with the virus. In a statement released ... 94 percent of air passengers from Guinea, Liberia ... these five airports -- New York City,s Kennedy ...
(Date:10/22/2014)... California (PRWEB) October 22, 2014 Hay House ... Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written ... of Yoga & Recovery. This book is meant to ... in a life of recovery. , Recovery 2.0 is ... 12 Steps; Recovery 2.0 is a guide for what comes ...
(Date:10/22/2014)... 22, 2014 Best Cheap Hosting USA ... world. The site has recently announced that iPower ( ... for people from around the world. , “iPower is ... today and is providing various kinds of useful products ... insists on offering excellent customer service and a number ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, October ... complimentary registration available at: http://bit.ly/1yStiU9 ... Vidyasekar and Visionary Innovation Research Group Senior ... electricity, self-assembling materials, nanobots and flexible electronics ... will transform our lives in the coming ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)... , Oct. 20, 2014  Luoxis Diagnostics, ... MKT: AMPE), today announced that its academic collaborators ... and research potential for its novel RedoxSYS Diagnostic ... (ORP) in the body in response to injury ... of ORP as a clinical marker will be ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
Cached News: